1. U. S. Department of Health and Human Services, Food and Drug Administration. The Benefits and Risks of Systemic Fluoroquinolone Antibacterial Drugs for the Treatment of Acute Bacterial Sinusitis (ABS), Acute Bacterial Exacerbation of Chronic Bronchitis in Patients Who Have Chronic Obstructive Pulmonary Disease (ABECB-COPD), and Uncomplicated Urinary Tract Infections (uUTI). 2015. Available from https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM467387.pdf. Cited 02 Jun 2017.
2. U. S. Department of Health and Human Services, Food and Drug Administration. Labeling revision: supplement approval letter (NDA 21158/S-018). 2011. Available from http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/021158s018ltr.pdf. Cited 02 Jun 2017.
3. Ofloxacin-associated retinopathy in rabbits: role of oxidative stress;S Rampal;Human & experimental toxicology,2008
4. Serous macular detachment of the neuro-epithelium and flumequine;D Sirbat;Journal français d'ophtalmologie,1983
5. Ocular side effects of flumequine. 3 cases of macular involvement;B Hurault de Ligny;Therapie,1984